mostc Dulaglutide Retatrutide| china
COA
Industrial Grade
40%
广东
dcvpeptides
40mg*10 vials
2026-06-28
Peptides,Retatrutide,GHK-CU
-
Product Description
-
Seller Information
-
DescriptionCertificatesBasic Info
-
Product Name:
mostc
Categories:
Research-
Class:
GLP-1 receptor agonist (GLP-1 analog fused to human IgG4-Fc, long-acting)
Status:FDA-approved (Trulicity 2014)
Mechanism:A long-acting GLP-1 receptor agonist consisting of a modified human GLP-1 molecule (7-37) covalently linked to a modified human IgG4 Fc fragment via a small peptide linker. The Fc fusion extends the half-life to ~5 days, allowing once-weekly dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying.
Activity note:Dulaglutide is a dual-agonist with GLP-1R activation. The exact EC50 is proprietary; functional potency is comparable to other long-acting GLP-1R agonists.
Source:DrugBank: DB09095; PubChem CID 16135271.
Clinical Development:FDA:Trulicity (approved 2014-09-18)
References-
DrugBank:PubChem:Disclaimer:
Dulaglutide is FDA-approved as a prescription medicine (Trulicity) for type 2 diabetes. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Peptides,Retatrutide,GHK-CU
-
Location:
Room 503, 5th Floor, Office Unit 501, New Triumphal Arch Health Products Mall, Changzheng Road, Chengguan Town, Taihe County, Fuyang City, Anhui Province
-
Payment Terms:
TT against copy of documents,D/P,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
3
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product